Qube Research & Technologies (QRT)
NPCE icon

Qube Research & Technologies (QRT)’s Neuropace NPCE Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.45M Sell
186,189
-12,808
-6% -$192K ﹤0.01% 2047
2025
Q4 		$3.07M Sell
198,997
-14,776
-7% -$198K ﹤0.01% 2035
2025
Q3 		$2.2M Buy
213,773
+101,136
+90% +$954K ﹤0.01% 2199
2025
Q2 		$1.25M Buy
112,637
+48,175
+75% +$602K ﹤0.01% 2380
2025
Q1 		$792K Buy
+64,462
New +$807K ﹤0.01% 2356
2024
Q4 		– Sell
-10,573
Closed -$73.7K – 3715
2024
Q3 		$73.7K Buy
10,573
+1,740
+20% +$12.7K ﹤0.01% 2787
2024
Q2 		$66.8K Sell
8,833
-36,385
-80% -$367K ﹤0.01% 2680
2024
Q1 		$597K Buy
45,218
+19,016
+73% +$271K ﹤0.01% 2440
2023
Q4 		$270K Buy
26,202
+23,803
+992% +$190K ﹤0.01% 2635
2023
Q3 		$23.3K Buy
+2,399
New +$14K ﹤0.01% 3105
2022
Q1 		– Sell
-19,086
Closed -$192K – 2821
2021
Q4 		$192K Buy
+19,086
New +$248K ﹤0.01% 1987

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Qube Research & Technologies (QRT)'s NPCE Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Neuropace (NPCE) stake by 6.4% in Q1 2026, selling an estimated $192K and leaving 186,189 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2047.

Qube Research & Technologies (QRT) first reported a position in NPCE in Q4 2021 and has held it in 11 quarters since. The position peaked at $3.07M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Qube Research & Technologies (QRT) held 186,189 shares of Neuropace worth $2.45M as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 12,808 Neuropace shares in Q1 2026, an estimated $192K.
  • Neuropace made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2047 holding.
  • Qube Research & Technologies (QRT) first reported a position in Neuropace in Q4 2021 and has held it in 11 quarters since.
  • Qube Research & Technologies (QRT)'s Neuropace position peaked at $3.07M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.